Literature DB >> 7713777

Chronic neuroendocrinological sequelae of radiation therapy.

C A Sklar1, L S Constine.   

Abstract

A variety of neuroendocrine disturbances are observed following treatment with external radiation therapy when the hypothalamic-pituitary axis (HPA) is included in the treatment field. Radiation-induced abnormalities are generally dose dependent and may develop many years after irradiation. Growth hormone deficiency and premature sexual development can occur following doses as low as 18 Gy fractionated radiation and are the most common neuroendocrine problems noted in children. Deficiency of gonadotropins, thyroid stimulating hormone, and adrenocorticotropin are seen primarily in individuals treated with > 40 Gy HPA irradiation. Hyperprolactinemia can be seen following high-dose radiotherapy (> 40 Gy), especially among young women. Most neuroendocrine disturbances that develop as a result of HPA irradiation are treatable; patients at risk require long-term endocrine follow-up.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713777     DOI: 10.1016/0360-3016(94)00427-M

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

Review 1.  Treating cancer patients. Practical monitoring and management of therapy-related complications.

Authors:  M Brigden; M McKenzie
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

Review 2.  Endocrine sequelae of cancer therapy in childhood.

Authors:  F B Diamond; B B Bercu
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

3.  Target Gland Dysfunction Following External Cranial Radiation for Extrasellar Tumours.

Authors:  M K Garg
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Bone density in post-pubertal adolescent survivors of childhood brain tumors.

Authors:  Laurie E Cohen; Joshua H Gordon; Erica Y Popovsky; Nina N Sainath; Henry A Feldman; Mark W Kieran; Catherine M Gordon
Journal:  Pediatr Blood Cancer       Date:  2011-08-29       Impact factor: 3.167

Review 5.  Orthodontic Therapy for Paediatric Cancer Survivors: A Review.

Authors:  Sumita Mishra
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 6.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

7.  Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: a report from the St Jude lifetime cohort study.

Authors:  Daniel M Green; Liang Zhu; Nan Zhang; Charles A Sklar; Raymond W Ke; William H Kutteh; James L Klosky; Sheri L Spunt; Monika L Metzger; Fariba Navid; DeoKumar Srivastava; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

8.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 9.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Abnormal perfusion of the pituitary gland secondary to dural arteriovenous fistulas in the cavernous sinus: dynamic MR findings.

Authors:  Yoshinori Shigematsu; Yukunori Korogi; Mika Kitajima; Akihiko Ishii; Luxia Liang; Masayuki Yamura; Kouich Kawanaka; Mutsumasa Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.